TITLE

Safety and Efficacy Review of Inhaled Loxapine for Treatment of Agitation

AUTHOR(S)
Currier, Glenn; Walsh, Patrick
PUB. DATE
April 2013
SOURCE
Clinical Schizophrenia & Related Psychoses;Apr2013, Vol. 7 Issue 1, p25
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Agitation is common in patients with acute schizophrenia and bipolar disorder, and rapid and effective treatment of acute agitation is an important clinical goal. Loxapine is a first-generation antipsychotic medication available in the United States in oral form for more than three decades. In December 2012, an inhaled version of vaporized loxapine was approved by the U.S. FDA for the treatment of agitated adults in the context of schizophrenia or bipolar disorder. In this review, we examine available literature to describe efficacy and safety of inhaled loxapine in healthy patients and in those with pulmonary compromise. Limitations of the current evidence base to predict efficacy in 'real world' patients are described, and safeguards necessary for appropriate use in psychiatric acute care settings are discussed.
ACCESSION #
86447510

 

Related Articles

  • FDA Actions. Elliott, William T. // Infectious Disease Alert;Jul2009 Supplement, p2 

    The article reports on the need for two topical testosterone gel products to carry boxed warnings on their labeling following a ruling by the U.S. Food and Drug Administration (FDA) that the gels may cause adverse effects in children who are exposed by contact with adults who are using the...

  • FDA approves new antipsychotic. Traynor, Kate // American Journal of Health-System Pharmacy;2/1/2007, Vol. 64 Issue 3, p222 

    The article reports on the approval of the new antipsychotic drug, paliperidone extended-release tablets for the treatment of schizophrenia, by the Food and Drug Administration (FDA) and Janssen L.P. in the U.S. Paliperidone is the active metabolite of the atypical antipsychotic drug...

  • New formulation.  // Formulary;Feb2007, Vol. 42 Issue 2, p80 

    The article reports on the approval of the aripiprazole for the treatment of agitation associated with schizophrenia or bipolar disease by the U.S. Food and Drug Administration (FDA). Aripiprazole has been approved by the FDA after its effectiveness was proven through placebo-controlled trials....

  • New Warning on Antipsychotic Drugs Used to Treat Older People.  // FDA Consumer;Jul/Aug2005, Vol. 39 Issue 4, p2 

    Reveals that the U.S. Food & Drug Administration (FDA) has issued a public health advisory on the unapproved use of several antipsychotic drugs to treat behavioral disorders in older people. List of the drugs that are approved only for the treatment of schizophrenia and mania; Request of the...

  • Eli Lilly: further Zyprexa Adhera delays benefit Johnson & Johnson.  // PharmaWatch: CNS;Feb2009, Vol. 8 Issue 2, p10 

    The article reports on the preparations of Eli Lilly & Co. for the proposed risk evaluation mitigation strategy for Zyprexa Adhera, a maintenance treatment for adults with schizophrenia. It states that the move was made by the company in response to the request of the Food and Drug...

  • Teva wins FDA approval for generic schizophrenia drug.  // PharmaWatch: CNS;Mar2009, Vol. 8 Issue 3, p11 

    The article reports on the approval of the Teva's generic schizophrenia drug from U.S. Food and Drug Administration. It states that the company was granted to market its generic version of Janssen's antipsychotic agent Risperdal oral solution. It adds that Teva was given a 180-day period to...

  • J&J files multiple applications for antipsychotic drugs.  // PharmaWatch: CNS;Mar2009, Vol. 8 Issue 3, p11 

    The article reports on the multiple applications filed by Johnson & Johnson (J&J) for antipsychotic drugs. It states that the approval of antipsychotic drug would expand the treatment options for patients diagnosed with schizophrenia or schizoaffective disorder. It notes that the J&J has...

  • Fanapt.  // Pharmaceutical Representative;Jul2009, Vol. 39 Issue 7, p11 

    The article reports on the U.S. Food and Drug Administration's (FDA's) approval of Fanapt (Iloperidone) from Vanda Pharmaceuticals Inc. to treat schizophrenia. It notes that the drug was first developed by Hoechst and licensed to Titan Pharmaceuticals. The company plans to make the drug...

  • Asenapine. Meltzer, Herbert Y.; Dritselis, Argyris; Yasothan, Uma; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Nov2009, Vol. 8 Issue 11, p843 

    In August 2009, asenapine (Saphris; Schering-Plough) was approved by the US FDA for the acute treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adults.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics